Cytogam®: Reducing the risk in high-risk transplants for over 17 years

Cytomegalovirus (CMV) is the most common and single most important viral infection in solid organ transplant recipients.1,2 Symptomatic disease occurs in approximately 39% of lung, 25% of heart, 29% of liver, up to 50% of pancreas, and 8% of renal transplant recipients not receiving antiviral prophylaxis.3

Cytogam® (Cytomegalovirus Immune Globulin Intravenous (CMV-IGIV)) can help protect patients against the CMV threat.

Cytogam® is the only IGIV product indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart.

Alone or in combination with an antiviral agent, Cytogam® has been shown to:

  • Reduce the risk of CMV-related disease and death in some of the highest-risk transplant patients1,2,4,5,6
  • Provide a measurable long-term survival benefit4
  • Produce minimal treatment-related side effects and adverse events

Cytogam®: Now backed by CSL Behring with over 100 years' expertise in plasma therapy

On December 18, 2006, CSL Behring completed the purchase of Cytogam® from MedImmune, Inc. In doing so, CSL Behring brought a new promise to Cytogam® that includes:

  • Innovation, quality, and deep insights to the field of organ transplant therapy
  • Expertise in plasma therapy to bring a safe supply of Cytogam® to transplant healthcare professionals
  • Partnering with transplant healthcare professionals to ensure that patients can obtain the high-quality products they need


1. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317:1049-54.

2. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1993;119:984-91.

3. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10(1):86-124.

4. Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation. 2001;72:1647-52.

5. Ham JM, Shelden SL, Godkin RR, Posner MP, Fisher RA. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction. Transplant Proc. 1995;27(5)Suppl 1:31-3.

6. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1993;119:984-91.